Evidence map›Paper›PMID 32269051›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2020

Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma.

Benjamin M Ellingson, Jingwen Yao, Catalina Raymond, David A Nathanson, Ararat Chakhoyan, Jeremy Simpson, James S Garner, Alan G Olivero, Lars U Mueller, Jordi Rodon and 3 more

Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01547546 (An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01547546 phase1completednot on this map

An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma

TypeinterventionalSponsorGenentech, Inc.Ran2012 to 2015Enrolled29ConditionsGlioblastoma, GliomaArmsGDC-0084
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Balancing Risk and Efficiency in Drug Development for Rare and Challenging Tumors: A New Paradigm for Glioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Review
  7. Review
  8. Article
  9. Review
  10. Multi-threshold volumetricNeuro-oncology advances
    Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 4 countries.

Benjamin M EllingsonUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California. bellingson@mednet.ucla.edu.ORCID 0000-0002-2764-6640
Jingwen YaoUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California.
Catalina RaymondUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California.
David A NathansonDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Ararat ChakhoyanUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California.
Jeremy SimpsonKazia Therapeutics Limited, Sydney, New South Wales, Australia.
James S GarnerKazia Therapeutics Limited, Sydney, New South Wales, Australia.
Alan G OliveroGenentech, Inc., South San Francisco, California.
Lars U MuellerGenentech, Inc., South San Francisco, California.
Jordi RodonVall d'Hebron Institute of Oncology, Barcelona, Spain.
Elizabeth GerstnerDepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts.
Timothy F CloughesyUCLA Neuro-Oncology Program, University of California, Los Angeles, Los Angeles, California.
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
APLA Health · USAmgen (United States) · USKazia Therapeutics (Australia) · AUDana-Farber Cancer Institute · USHebron University · PSMassachusetts General Hospital · USUniversity of California, Los Angeles · US

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Metabolic MRI for quantifying aerobic glycolysis and immune function in gliomasR21CA223757 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ELLINGSON, BENJAMIN M. · 2018 to 2019
$366k
NCI NIH HHS P50 CA211015NCI NIH HHS R21 CA223757
6 · The paper itself

Abstract

purposeGDC-0084 is an oral, brain-penetrant small-molecule inhibitor of PI3K and mTOR. Because these two targets alter tumor vascularity and metabolism, respectively, we hypothesized multiparametric MR-PET could be used to quantify the response, estimate pharmacokinetic (PK) parameters, and predict progression-free survival (PFS) in patients with recurrent malignant gliomas. PATIENTS AND

methodsMultiparametric advanced MR-PET imaging was performed to evaluate physiologic response in a first-in-man, multicenter, phase I, dose-escalation study of GDC-0084 (NCT01547546) in 47 patients with recurrent malignant glioma.

resultsMeasured maximum concentration (

conclusionsResults from this study suggest composite biomarkers created from multiparametric MR-PET imaging targeting metabolic and/or physiologic processes specific to the drug mechanism of action may be useful for subsequent evaluation of treatment efficacy for larger phase II-III studies.

Indexed as

Magnetic Resonance ImagingPositron-Emission TomographyAdultAgedBrainFemaleGliomaHumansImage Processing, Computer-AssistedMaleMiddle AgedMolecular Targeted TherapyNeoplasm GradingOxazinesPrognosisProgression-Free SurvivalGDC-0084OxazinesProtein Kinase InhibitorsPyrimidines

Identifiers

PMID32269051
PMCPMC8204664
OpenAlexW3015396224

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.